Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/199864
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwon, Mi | - |
dc.contributor.author | Iacoboni, Gloria | - |
dc.contributor.author | Reguera, Juan Luís | - |
dc.contributor.author | López Corral, Lucía | - |
dc.contributor.author | Hernani Morales, Rafael | - |
dc.contributor.author | Ortiz-Maldonado Gibson, Valentín | - |
dc.contributor.author | Guerreiro, Manuel | - |
dc.contributor.author | Caballero, Ana Carolina | - |
dc.contributor.author | Guerra Domínguez, Luisa | - |
dc.contributor.author | Sánchez Pina, Jose Maria | - |
dc.contributor.author | Mussetti, Alberto | - |
dc.contributor.author | Sancho, Juan Manuel | - |
dc.contributor.author | Bastos Oreiro, Mariana | - |
dc.contributor.author | Catala, Eva | - |
dc.contributor.author | Delgado, Javier | - |
dc.contributor.author | Luzardo Henriquez, Hugo | - |
dc.contributor.author | Sanz, Jaime | - |
dc.contributor.author | Calbacho, María | - |
dc.contributor.author | Bailén, Rebeca | - |
dc.contributor.author | Carpio, Cecilia | - |
dc.contributor.author | Ribera, Josep Maria | - |
dc.contributor.author | Sureda, Anna | - |
dc.contributor.author | Briones, Javier | - |
dc.contributor.author | Hernández Boluda, Juan Carlos | - |
dc.contributor.author | Martínez Cebrián, Nuria | - |
dc.contributor.author | Diez Martin, Jose Luis | - |
dc.contributor.author | Martín, Alejandro | - |
dc.contributor.author | Barba, Pere | - |
dc.date.accessioned | 2023-06-26T10:49:55Z | - |
dc.date.available | 2023-06-26T10:49:55Z | - |
dc.date.issued | 2022-06-30 | - |
dc.identifier.issn | 1592-8721 | - |
dc.identifier.uri | http://hdl.handle.net/2445/199864 | - |
dc.description.abstract | Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We performed a retrospective study to evaluate safety and efficacy of axi-cel and tisa-cel outside the setting of a clinical trial. Data from consecutive patients with R/R LBCL who underwent apheresis for axi-cel or tisa-cel were retrospectively collected from 12 Spanish centers. A total of 307 patients underwent apheresis for axi-cel (n=152) and tisa-cel (n=155) from November 2018 to August 2021, of which 261 (85%) received a CAR T infusion (88% and 82%, respectively). Median time from apheresis to infusion was 41 days for axi-cel and 52 days for tisa-cel (P=0.006). None of the baseline characteristics were significantly different between both cohorts. Both cytokine release syndrome and neurologic events (NE) were more frequent in the axi-cel group (88% vs. 73%, P=0.003, and 42% vs. 16%, P<0.001, respectively). Infections in the first 6 months post-infusion were also more com -mon in patients treated with axi-cel (38% vs. 25%, P=0.033). Non-relapse mortality was not significantly different between the axi-cel and tisa-cel groups (7% and 4%, respectively, P=0.298). With a median follow-up of 9.2 months, median PFS and OS were 5.9 and 3 months, and 13.9 and 11.2 months for axi-cel and tisa-cel, respectively. The 12-month PFS and OS for axi-cel and tisa-cel were 41% and 33% (P=0.195), 51% and 47% (P=0.191), respectively. Factors associated with lower OS in the multivariate analysis were increased lactate dehydrogenase, ECOG >= 2 and progressive disease before lympho-depletion. Safety and efficacy results in our real-world experience were comparable with those reported in the pivotal trials. Patients treated with axi-cel experienced more toxicity but similar non-relapse mortality compared with those re-ceiving tisa-cel. Efficacy was not significantly different between both products. | - |
dc.format.extent | 12 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Ferrata Storti Foundation (Haematologica) | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3324/haematol.2022.280805 | - |
dc.relation.ispartof | Haematologica, 2022, vol. 108, num. 1, p. 110-121 | - |
dc.relation.uri | https://doi.org/10.3324/haematol.2022.280805 | - |
dc.rights | cc by-nc (c) Kwon, Mi et al, 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Cèl·lules B | - |
dc.subject.classification | Limfomes | - |
dc.subject.other | B cells | - |
dc.subject.other | Lymphomas | - |
dc.title | Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-06-23T10:33:44Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 35770532 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
10697-Article Text-78641-2-10-20221227.pdf | 927.83 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License